Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Lung Cancers

37 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Melanoma
    Non Small Cell

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    Lung
    Non Small Cell
    Small Cell

    VICCTHO0398

    12/04/2003

    Molecular Predictors of Lung Cancer Behavior. (SPORE)

    Basic Science

    Lung
    Non Small Cell

    VICCTHO0136

    05/01/2001

    Molecular Fingerprinting of Lung Cancer (SPORE)

    Other

    Lung

    VICCTHO15123

    05/20/2016

    The PERCEPTA Registry

    Other

    Lung
    Non Small Cell

    ECOGTHOA151216

    09/17/2015

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    Other

    Lung
    Miscellaneous
    Small Cell

    VICCMD1494

    10/31/2014

    Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

    Supportive Care

    Lung

    VICCTHO1657

    10/14/2016

    A Pivotal Multi-Center, Randomized, Controlled, Single-Blinded Study Comparing the Silver Nitrate-Coated Indwelling Pleural Catheter (SNCIPC) to the Uncoated PleurX? Pleural Catheter for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions

    Treatment

    Lung

    VICCTHO1691

    04/25/2017

    A Phase II Single-Arm Trial to Investigate Tepotinib in advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-Doublet-Containing Regimen

    Treatment

    Bladder
    Breast
    Colon
    Gastric/Gastroesophageal
    Head/Neck
    Liver
    Lung
    Melanoma
    Non Small Cell
    Ovarian
    Pancreatic
    Rectal
    Sarcoma

    VICCMD1605

    03/28/2017

    Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors

    Treatment

    Head/Neck
    Lung
    Melanoma
    Non Small Cell

    VICCMD1636

    12/21/2016

    A Phase 1b/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

    Treatment

    Lung
    Melanoma
    Non Small Cell

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma

    Treatment

    Lung
    Neuroendocrine

    VICCTHO15115

    11/08/2016

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumor Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Ovarian
    Uterine

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Lung
    Small Cell

    NRGTHOCC003

    10/24/2016

    Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

    Treatment

    Gastric/Gastroesophageal
    Liver
    Lung

    VICCPHI15114

    09/28/2016

    An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Lung
    Non Small Cell

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Treatment

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    Lung

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    Lung
    Small Cell

    VICCTHO15117

    05/19/2016

    A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

    Treatment

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Bladder
    Breast
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Gynecologic
    Head/Neck
    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell
    Pancreatic
    Rectal
    Urologic
    Uterine

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    Lung

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti−PDL1 Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine For PD L1-Selected Chemotherapy-Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    ECOGTHOE4512

    09/15/2015

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    Treatment

    Lung
    Small Cell

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    Lung

    CTSUTHOS1400

    01/20/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    Lung

    ECOGTHO2511-M

    11/04/2014

    Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

    Treatment

    Lung

    THOMK3475-024-M

    08/05/2014

    MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

    Treatment

    Lung
    Non Small Cell

    VICCTHN1244

    07/25/2012

    Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer

    Treatment

    Non Small Cell

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Treatment

    Lung

    ECOGTHO4508-M

    12/07/2010

    Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

    Treatment

    Lung

    CTSUTHOC30607-M

    02/17/2010

    ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

    Treatment

    Non Small Cell

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor